Roche/Genentech’s late-stage pipeline is bubbling with blockbusters headed for make-or-break FDA decisions. Incredibly, the biggest new drug of all isn’t even in cancer.
Roche/Genentech’s late-stage pipeline is bubbling with blockbusters headed for make-or-break FDA decisions. Incredibly, the biggest new drug of all isn’t even in cancer.